艾美疫苗(06660.HK)无血清迭代狂犬疫苗上市注册获受理

阿斯达克财经
08 Apr

艾美疫苗(06660.HK) 公布,集团研发的无血清迭代狂犬疫苗上市注册获国家药品监督管理局受理。此外,全资子公司艾美荣誉(宁波)已于近日取得无血清迭代狂犬疫苗相应的产品生产许可证。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10